Items where authors include "Labeit, S"
Up a levelArticle
Adams, V, Schauer, A, Augstein, A et al. (11 more authors) (2022) Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility. Journal of Cachexia, Sarcopenia and Muscle, 13 (3). pp. 1565-1581. ISSN 2190-5991
Labeit, S, Hirner, S, Bogomolovas, J et al. (5 more authors) (2021) Regulation of Glucose Metabolism by MuRF1 and Treatment of Myopathy in Diabetic Mice with Small Molecules Targeting MuRF1. International Journal of Molecular Sciences, 22 (4). 2225. pp. 1-15. ISSN 1661-6596
Scalabrin, M, Adams, V, Labeit, S et al. (1 more author) (2020) Emerging Strategies Targeting Catabolic Muscle Stress Relief. International Journal of Molecular Sciences, 21 (13). 4681. ISSN 1661-6596
Nguyen, T, Bowen, TS, Augstein, A et al. (5 more authors) (2020) Expression of MuRF1 or MuRF2 is essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model. Skeletal Muscle, 10 (1). 12. ISSN 2044-5040
Adams, V, Bowen, TS, Werner, S et al. (15 more authors) (2019) Small‐molecule‐mediated chemical knock‐down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 10 (5). pp. 1102-1115. ISSN 2190-5991
Bowen, TS, Adams, V, Werner, S et al. (10 more authors) (2017) Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. Journal of Cachexia, Sarcopenia and Muscle, 8 (6). pp. 939-953. ISSN 2190-5991
Conference or Workshop Item
Adams, V, Nguyen, T, Bowen, TS et al. (3 more authors) (2018) Murf1 and Murf2 Independently Mediate Muscle Wasting in Mice With Cardiac Cachexia. In: 2018 American Heart Association Scientific Sessions, 10-14 Nov 2018, Chicago, Illinois, USA.